Pet Health
Immune-Mediated Hemolytic Anemia in Dogs
Immune-mediated hemolytic anemia (IMHA) in dogs is a serious disease in which the immune system destroys the dog's own red blood cells.
Key takeaways
Immune-mediated hemolytic anemia (IMHA) in dogs is a serious disease in which the immune system destroys the dog's own red blood cells.
- Canine IMHA is a potentially life-threatening condition that can develop gradually or progress into a medical crisis within a short time.
- As red blood cells are destroyed, the body loses its ability to deliver enough oxygen to tissues and organs.
- Early veterinary assessment is essential, even when symptoms initially appear mild.
- If a dog develops sudden weakness, pale or yellow gums, fever, marked lethargy, or red-brown urine, emergency veterinary care is necessary.
- Waiting to see whether these signs improve can allow the anemia to become more severe.
What Is Immune-Mediated Hemolytic Anemia in Dogs?
Immune-mediated hemolytic anemia occurs when the immune system mistakenly identifies the dog's own red blood cells as foreign and produces antibodies that target them for destruction.
This process is called hemolysis.
Red blood cells normally transport oxygen throughout the body. When they are destroyed faster than the bone marrow can replace them, the dog develops anemia, potentially reducing oxygen delivery to vital organs.
The destruction can happen in two main ways:
• Extravascular hemolysis: Antibody-coated red blood cells are removed and destroyed by immune cells, particularly macrophages in the spleen and liver.
• Intravascular hemolysis: Red blood cells break apart within the bloodstream, releasing hemoglobin into the circulation.
Both processes can cause severe anemia and increased bilirubin, which contributes to jaundice.
Veterinarians classify canine IMHA into two broad categories:
• Primary IMHA: Also called idiopathic IMHA, this occurs when diagnostic investigation does not identify an underlying cause.
• Secondary IMHA: This occurs when an underlying disease, infection, medication exposure, or other associated condition is identified as a possible trigger.
Finding an associated condition does not automatically establish that it caused the immune reaction.
Immune-Mediated Hemolytic Anemia in Dogs: Symptoms
Symptoms depend on how quickly red blood cells are being destroyed and how severely the anemia affects the dog.
Some dogs develop gradual changes, while others become critically ill with little warning.
Common symptoms include:
• Pale gums: Reduced red blood cell levels can make the gums appear unusually pale or almost white.
• Yellow gums, skin, or eyes: Jaundice develops when bilirubin accumulates as red blood cells are destroyed.
• Weakness and lethargy: Reduced oxygen delivery can cause unusual tiredness, difficulty moving, and decreased activity.
• Loss of appetite: Affected dogs may eat less or refuse food.
• Fever: Some dogs develop an elevated body temperature.
• Rapid heartbeat: The heart may beat faster as the body attempts to compensate for reduced oxygen delivery.
• Enlarged spleen: The spleen may become enlarged during the immune-mediated destruction process.
• Dark or reddish urine: Hemoglobin released during intravascular hemolysis can enter the urine and cause discoloration.
Early symptoms versus severe symptoms
Early IMHA can look like an ordinary illness. A dog may initially appear tired, eat less, or seem less interested in normal activities. These changes should not be dismissed, particularly if the gums also appear pale or yellow.
More advanced disease can involve severe weakness, rapidly worsening anemia, jaundice, and complications involving blood clot formation.
When to seek emergency care: Pale or yellow gums, sudden weakness, red-brown urine, fever accompanied by marked lethargy, or rapid deterioration warrant immediate veterinary assessment. A dog with suspected IMHA should not be monitored at home in place of an examination and blood testing.
What Causes Immune-Mediated Hemolytic Anemia in Dogs?
IMHA develops when immune defenses mistakenly attack red blood cells.
However, the reason this happens is not always identifiable.
Potential underlying conditions and associated factors include the following.
Infections
Certain infections can contribute to immune dysfunction and red blood cell destruction. Blood-borne and vector-borne infections are particularly important to investigate.
Babesia species are among the infectious organisms associated with canine IMHA. Other organisms that may warrant investigation include Anaplasma, Ehrlichia, and Bartonella, depending on the dog's location, travel history, and exposure risks.
Cancer
Some cancers, particularly those involving lymphatic or immune-system tissues, have been associated with immune-mediated destruction of red blood cells. Veterinary investigation may include imaging and other tests to look for underlying tumors.
Medications and toxins
Some medication exposures have been associated with immune-mediated blood disorders, although the strength of evidence varies considerably among individual drugs. Toxin exposure can also cause red blood cell destruction through mechanisms that may resemble IMHA.
A complete medication history is important, including prescription drugs, over-the-counter products, supplements, and previous treatments.
Inflammatory and immune-system conditions
Systemic inflammatory conditions and other immune-system disorders may be investigated when looking for a possible underlying trigger. However, evidence directly establishing many noninfectious inflammatory conditions as causes of canine IMHA remains limited.
Vaccinations
Vaccination has been investigated as a possible trigger for IMHA, but the available evidence does not establish a conclusive causal relationship. The ACVIM consensus statement considers current vaccination strategies generally safe while recommending that individual risks and benefits be considered.
A recent vaccination should be included in the dog's medical history, but its timing alone does not prove that it caused the anemia.
When no cause is identified
Many dogs are classified as having primary or idiopathic IMHA because testing does not reveal an underlying cause. This does not mean the disease is less serious or that treatment is unnecessary.
How Is IMHA Diagnosed in Dogs?
Diagnosing canine IMHA requires more than finding anemia on a routine blood test.
Veterinarians must establish that red blood cells are being destroyed and gather evidence that the immune system is responsible.
There is no single universally accepted diagnostic gold-standard test for IMHA. The diagnosis is based on a combination of laboratory findings, clinical signs, and investigation of alternative explanations.
Complete blood count and hematocrit
A complete blood count (CBC) measures red blood cells, white blood cells, and platelets.
The packed cell volume (PCV), also called hematocrit (Hct), helps determine how much of the blood consists of red blood cells. These measurements help establish the severity of anemia and track changes during treatment.
A reticulocyte count measures immature red blood cells and helps assess whether the bone marrow is responding to anemia.
Importantly, a lack of increased reticulocytes does not rule out IMHA. Approximately 30% of dogs with IMHA have nonregenerative anemia when first examined.
Blood smear examination
A blood smear allows the laboratory to examine the shape and appearance of individual red blood cells.
One important finding is spherocytosis, the presence of unusually rounded red blood cells called spherocytes. These cells can provide evidence of immune-mediated red blood cell destruction in dogs.
The smear can also help identify abnormalities that suggest other causes of anemia, including certain blood parasites and red blood cell damage.
Direct antiglobulin test
The direct antiglobulin test (DAT), commonly called the Coombs test, looks for antibodies or complement attached to red blood cells.
A positive result can support an IMHA diagnosis, but the test is not completely sensitive or specific. A negative result does not automatically exclude the disease.
Saline agglutination test
This test evaluates whether red blood cells clump together when mixed with saline.
Persistent clumping after appropriate dilution or washing can provide evidence of immune-mediated destruction. The veterinarian interprets this result alongside the other diagnostic findings.
Testing for hemolysis
Additional tests look for evidence that red blood cells are actively breaking down.
These may include:
• Increased bilirubin in the blood.
• Jaundice.
• Hemoglobin in the bloodstream.
• Hemoglobin in the urine.
• Spherocytes on blood smear examination.
The ACVIM diagnostic approach combines evidence of anemia, immune-mediated red blood cell destruction, and hemolysis rather than relying on an isolated abnormal result.
Investigating underlying causes
A complete diagnostic evaluation may include:
• Blood chemistry testing to assess organ function.
• Urinalysis.
• Blood smear examination.
• Testing for Babesia using serology and PCR.
• Additional infectious disease testing based on geographic and exposure risks.
• Abdominal imaging when cancer or another underlying condition is suspected.
• Abdominal radiographs to investigate possible zinc toxicity.
The veterinarian will also review vaccination history, previous illnesses, medications, tick exposure, travel, and possible toxin exposure.
Immune-Mediated Hemolytic Anemia in Dogs: Treatment
Treatment aims to stop immune-mediated destruction of red blood cells, restore adequate oxygen delivery, prevent complications, and address any underlying disease that may be contributing to the condition.
Because IMHA can progress rapidly, many affected dogs require hospitalization and intensive monitoring, particularly during initial stabilization.
1. Immunosuppressive medications
Immunosuppressive treatment is the foundation of managing primary canine IMHA.
Prednisone or prednisolone, which are corticosteroid medications, are commonly used to suppress the immune response responsible for attacking red blood cells.
For dogs with severe disease, an inadequate response, continued transfusion requirements, or significant corticosteroid-related adverse effects, an additional immunosuppressive medication may be considered. Options described in the ACVIM treatment guidelines include:
• Azathioprine.
• Cyclosporine.
• Mycophenolate mofetil.
The choice depends on disease severity, response to initial treatment, potential adverse effects, and the dog's individual circumstances. Evidence has not established that one additional immunosuppressive medication is consistently superior to the others.
2. Blood transfusions
A blood transfusion may be necessary when anemia significantly reduces the amount of oxygen reaching the body's tissues.
Packed red blood cells are generally preferred when transfusion is required. Whole blood may be used when packed red blood cells are unavailable.
The decision to transfuse depends on factors such as:
• Severity of clinical signs.
• Speed at which anemia is developing.
• PCV or hematocrit.
• Evidence of inadequate tissue oxygen delivery.
• The ability to monitor the dog closely.
There is no single blood count that determines the need for a transfusion in every dog.
A transfusion supports oxygen delivery but does not independently stop the immune system from destroying red blood cells. Immunosuppressive treatment remains important.
3. Prevention of blood clots
Blood clot formation is one of the most serious complications of canine IMHA.
Dogs with this condition have an increased risk of thrombosis, including pulmonary thromboembolism, in which a clot obstructs blood flow through the lungs. This complication contributes substantially to illness and death in affected dogs.
The ACVIM treatment consensus recommends thromboprophylaxis for most dogs with IMHA, using veterinarian-selected antiplatelet or anticoagulant medications. Severe thrombocytopenia, meaning an unusually low platelet count, can change whether these medications are appropriate.
This is an important part of treatment even when a dog appears to be responding to immunosuppressive medication.
Aspirin or other clot-prevention medications should never be started independently. The choice must account for platelet levels, bleeding risk, and the dog's overall condition.
4. Intravenous fluids and supportive care
Hospital supportive care may include intravenous fluids to help maintain circulation and kidney function. Blood transfusions may be added when necessary.
Supportive treatment is individualized according to the dog's hydration, circulation, laboratory results, and complications.
5. Treatment of underlying conditions
If testing identifies an infection or another possible trigger, the veterinary team may need to treat that condition as part of the overall plan.
This can involve appropriate antimicrobial treatment or reviewing and discontinuing a suspected medication when medically appropriate. Necessary medications should not be stopped without veterinary direction.
Recovery, Monitoring, and Possible Complications
Recovery from IMHA requires more than seeing improved energy or appetite.
The veterinarian must confirm that red blood cell levels are stabilizing and that the signs of ongoing hemolysis are improving.
How long does treatment take?
Treatment commonly continues for several months.
The ACVIM treatment consensus describes a typical treatment duration of three to six months for prednisone or prednisolone and approximately four to eight months for all immunosuppressive treatment in the majority of cases. Individual treatment periods vary.
Medications must be reduced according to the dog's response and repeat laboratory findings. Stopping immunosuppressive treatment too early can allow the disease to become active again.
Bloodwork during recovery
Regular blood testing is essential during treatment.
The ACVIM consensus recommends checking PCV or hematocrit before medication reductions and monitoring these measurements every one to three weeks during treatment. Additional assessments can include blood smear examination, agglutination, bilirubin, and reticulocyte measurements.
These tests help determine whether red blood cell destruction is controlled and whether medication changes are appropriate.
Medication side effects
Corticosteroids and other immunosuppressive medications can cause significant adverse effects.
Common corticosteroid-related changes include:
• Increased thirst.
• More frequent urination.
• Increased appetite.
• Excessive panting.
• Muscle weakness or muscle loss.
Longer-term treatment can also increase susceptibility to infections and cause changes involving the skin, muscles, and metabolism.
Veterinary monitoring helps identify these complications and determine whether treatment needs adjustment.
Recognizing a possible relapse
IMHA can return after an initial improvement or remission.
Warning signs include renewed weakness, pale gums, jaundice, reduced appetite, and other symptoms associated with anemia. Owners should contact a veterinarian immediately if these changes appear.
The ACVIM consensus suggests continuing blood count monitoring for four weeks after complete recovery and discontinuation of all treatment to confirm treatment-free remission. Beyond that period, routine blood count testing is generally not considered necessary in a fully recovered dog, although owners should continue watching for clinical signs.
Prognosis: Can Dogs Recover From IMHA?
Dogs can respond to treatment and recover from immune-mediated hemolytic anemia, but the disease carries a substantial risk of serious complications and death.
Recovery is not guaranteed.
The initial period after diagnosis is particularly important. The ACVIM treatment consensus identifies the first two weeks after treatment begins as the period of greatest mortality risk.
Factors associated with a more concerning prognosis include:
• Rapidly decreasing red blood cell counts.
• Increased bilirubin or visible jaundice.
• Increased blood urea concentrations.
• Abnormal bruising.
• Excessive blood clot formation.
These findings can indicate more severe disease or complications.
A dog's outlook depends on the severity of anemia, the speed of disease progression, underlying conditions, complications, and response to treatment.
The most useful indicators of recovery are improving clinical condition, stable or increasing PCV or hematocrit, and improvement in laboratory markers of hemolysis.
Even when symptoms improve, continued monitoring and careful medication management remain important.
Frequently asked questions
Is immune-mediated hemolytic anemia painful for dogs?
IMHA does not necessarily cause obvious pain. Some dogs initially show weakness, tiredness, or reduced appetite without appearing uncomfortable. However, the disease can become severe and cause life-threatening complications even when obvious pain is absent.
Is IMHA in dogs fatal?
Yes, IMHA can be fatal. Severe anemia, ongoing red blood cell destruction, and complications such as pulmonary thromboembolism contribute to the risk. However, treatment can control the immune response and support recovery in some dogs.
Can a dog fully recover from immune-mediated hemolytic anemia?
Some dogs achieve complete remission and eventually stop immunosuppressive treatment. Recovery generally requires months of treatment and repeated bloodwork. A relapse remains possible, so owners should continue monitoring for signs of anemia.
Does a dog with IMHA always need a blood transfusion?
No. A transfusion is recommended when clinical signs indicate that reduced red blood cell levels are interfering with oxygen delivery. The decision depends on the individual dog's condition, the severity and speed of anemia, and the availability of intensive monitoring.
Can a negative Coombs test rule out IMHA?
No. The direct antiglobulin test, also called the Coombs test, is not completely sensitive. Veterinarians interpret its findings alongside blood smear results, saline agglutination testing, flow cytometry when available, and evidence of hemolysis.
Can immune-mediated hemolytic anemia return after treatment?
Yes. Relapses can occur, sometimes with sudden clinical deterioration. New weakness, pale or yellow gums, reduced appetite, or other signs of anemia should prompt immediate veterinary assessment.
Do vaccinations cause IMHA in dogs?
A definitive causal relationship has not been established. The available veterinary evidence is inconclusive, and the ACVIM consensus considers current vaccination strategies generally safe. Vaccination decisions should nevertheless account for the individual dog's medical history and circumstances.
Editorial standards
Who wrote this guide
Written by VetWayfinder Editorial Team.
Every factual statement is tied to a cited source listed below. Report an error through the corrections page.
Sources
Each source supports at least one factual statement in this guide.
